Kartik Anand

Osimertinib-Induced Cardiotoxicity

Kartik Anand, Joe Ensor, Barry Trachtenberg et al. · JACC CardioOncology · 2019 · 198 citations · Full text

Medicine, Oncology, Pharmacology +17

A phase 1/2 clinical trial of the nitric oxide synthase inhibitor L-NMMA and taxane for treating chemoresistant triple-negative breast cancer

Andrew W. Chung, Kartik Anand, Ann C. Anselme et al. · Science Translational Medicine · 2021 · 109 citations

Medicine, Oncology, Pharmacology +10

Mycobacterial infections due to PD-1 and PD-L1 checkpoint inhibitors

Kartik Anand, Geetanjali Sahu, Ethan Burns et al. · ESMO Open · 2020 · 71 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

Targeting mTOR and DNA repair pathways in residual triple negative breast cancer post neoadjuvant chemotherapy

Kartik Anand, Tejal Patel, Polly Niravath et al. · Scientific Reports · 2021 · 55 citations · Full text

Medicine, Oncology, Pharmacology +17

A Phase II Study of the Efficacy and Safety of Chloroquine in Combination With Taxanes in the Treatment of Patients With Advanced or Metastatic Anthracycline-refractory Breast Cancer

Kartik Anand, Polly Niravath, Tejal Patel et al. · Clinical Breast Cancer · 2020 · 54 citations · Full text

Medicine, Oncology, Pharmacology +13